Montag A & Associates Inc. Sells 3,407 Shares of Johnson & Johnson $JNJ

Montag A & Associates Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,820 shares of the company’s stock after selling 3,407 shares during the quarter. Montag A & Associates Inc.’s holdings in Johnson & Johnson were worth $15,727,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of JNJ. Pinnacle Holdings LLC increased its stake in Johnson & Johnson by 0.5% during the 3rd quarter. Pinnacle Holdings LLC now owns 11,214 shares of the company’s stock valued at $2,079,000 after purchasing an additional 54 shares in the last quarter. Great Lakes Retirement Inc. grew its holdings in shares of Johnson & Johnson by 5.7% during the third quarter. Great Lakes Retirement Inc. now owns 8,847 shares of the company’s stock valued at $1,640,000 after buying an additional 474 shares during the last quarter. FSA Advisors Inc. acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $406,000. Planning Alternatives Ltd. ADV bought a new stake in shares of Johnson & Johnson during the third quarter worth about $351,000. Finally, Managed Asset Portfolios LLC raised its holdings in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Managed Asset Portfolios LLC now owns 171,802 shares of the company’s stock worth $31,856,000 after acquiring an additional 951 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA Fast Track for nipocalimab in systemic lupus erythematosus (SLE) — designation follows positive Phase 2 data and a Phase 3 enrollment; this can speed review and raises the commercial potential of a new immunology asset. PR Newswire
• Positive Sentiment: Drug pipeline momentum: J&J reported encouraging early results for oncology candidate pasritamig and is preparing Phase 3 plans; continued progress across immunology and neuroscience (Tremfya, Caplyta, Spravato) is offsetting some revenue headwinds. Yahoo Finance
• Positive Sentiment: Market context: broader Dow strength is supporting JNJ’s move higher today as large-cap pharma recovers, giving momentum to shares. Kalkine Media
• Neutral Sentiment: Investor events and cadence: J&J scheduled an investor conference call for April 14 to review Q1 results — a routine event that could provide guidance/clarity but is not immediate catalyst. Business Wire
• Neutral Sentiment: Income appeal: J&J appears on several March dividend-stock lists, reinforcing steady-income investor interest but offering limited short-term price impact. Blockonomi
• Neutral Sentiment: Conference presentation material (TD Cowen transcript) gives investors detail on strategy and pipeline execution; useful for longer-term thesis but not an immediate mover. Seeking Alpha
• Negative Sentiment: Bayer legal action: Bayer has initiated a legal challenge related to prostate-cancer product claims — this creates regulatory and litigation risk that could weigh on sentiment and add to uncertainty. Yahoo Finance
• Negative Sentiment: Analyst stance: some sell-side notes (Bank of America reiteration/Hold) point to limited near-term upside despite better oncology estimates — tempers rally expectations. TipRanks

Wall Street Analyst Weigh In

A number of brokerages have commented on JNJ. Barclays boosted their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 30th. Wolfe Research upped their price target on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a report on Monday, January 5th. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a report on Thursday, January 22nd. Finally, Leerink Partners increased their target price on shares of Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $232.70.

Johnson & Johnson Stock Down 0.7%

Shares of NYSE:JNJ opened at $246.77 on Wednesday. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The company has a market capitalization of $594.69 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 2.41 and a beta of 0.34. The business has a fifty day moving average price of $226.32 and a two-hundred day moving average price of $203.01. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion for the quarter. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.